Shao et al. designed a nanosystem consisted of SWNTs, IGF1R monoclonal antibody (anti-IGF1R) and HER2 monoclonal antibody (anti-HER2), which could target IGF1R and HER2 in tumor cells [46]. This evidence concerns the gene ERBB2 and neoplasm.